Biotech Building Blocks On Trial: ACLU, Myriad Battle Over BRCA Cancer Gene Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
ACLU argues that isolated DNA molecules are like a carburetor taken from an engine, the same inside as outside the body; Myriad says they are new compositions of matter.
You may also be interested in...
Myriad's BRCA Gene Patents Struck Down In Court; Are Biotech's Foundations Shaking?
Judge finds that isolated DNA is not different from that in the body and thus unpatentable; Myriad says its products are covered by other patents.
Myriad's BRCA Gene Patents Struck Down In Court; Are Biotech's Foundations Shaking?
Judge finds that isolated DNA is not different from that in the body and thus unpatentable; Myriad says its products are covered by other patents.
Biotech's Patent Suite Catches Sparks From Federal Circuit's Prometheus Decision
Pharmaceutical and biotech firms will have broader patent protection after an appeals court drew a narrow definition of what constitutes a natural phenomenon in the biotech arena. Specifically, the court ruled that a test to measure a drug's metabolites in order to determine the proper drug dosage is patentable subject matter